Market Overview

UPDATE: Piper Jaffray Initiates Idera Pharmaceuticals at Overweight on Encouraging Data

Related IDRA
Idera Pharmaceuticals Expands Pipeline By Initiating Clinical Development Of Proprietary TLR Antagonist Candidate IMO-9200
Corporate Events for the Week of Jun. 2nd, 2014

Piper Jaffray initiated overage on Idera Pharmaceuticals (NASDAQ: IDRA) with an Overweight rating and a $2 price target.

Piper Jaffray commented, "Idera is developing IMO-3100, a TLR 7 and 9 antagonist, for the treatment of lupus. The company recently reported top-line data from a 4-week Phase IIa study of IMO-3100 in moderate-to-severe psoriasis showing a statistically significant improvement in the Psoriasis Area Severity Index (PASI) score over placebo. Not only do these results demonstrate proof-ofconcept for IMO-3100 in psoriasis, but more broadly Idera's approach of modulating TLRs to treat autoimmune disorders. The company next intends to conduct a larger, 12-week Phase IIb trial in early 2013. IMO-3100 offers a unique mechanism of action in a disease that needs novel therapies and could represent a blockbuster opportunity."

Idera Pharmaceuticals closed at $0.80 on Wednesday.

Latest Ratings for IDRA

DateFirmActionFromTo
Mar 2014Cowen & CompanyInitiates Coverage onOutperform
Jan 2013Piper JaffrayInitiates Coverage onOverweight

View More Analyst Ratings for IDRA
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (IDRA)

Around the Web, We're Loving...

Get Benzinga's Newsletters